Cadila Pharmaceuticals Issues Class 4 Defect Notification for Mirtazapine 30mg Tablets
The defect notification for Mirtazapine 30mg tablets raises concerns about supply chain integrity and patient access to this antidepressant. Monitoring the situation is crucial as it may lead to regulatory scrutiny and affect market dynamics.
Company
Cadila Pharmaceuticals
Asset
Cadila
Indication
Psychiatry / Antidepressant
Status
Under Review
Signal Score
6.8
Signal assessment
Signal strength
moderate
Confidence level
moderate
Strategic implication
The defect notification for Mirtazapine 30mg tablets raises concerns about supply chain integrity and patient access to this antidepressant. Monitoring the situation is crucial as it may lead to regulatory scrutiny and affect market dynamics.
Why it matters
The defect notification for Mirtazapine 30mg tablets raises concerns about supply chain integrity and patient access to this antidepressant. Monitoring the situation is crucial as it may lead to regulatory scrutiny and affect market dynamics.
What changed
Safety Signal
Analysis
Cadila Pharmaceuticals Limited reported a defect in the EAN barcode on Mirtazapine 30mg tablets, affecting distribution.
The defect notification for Mirtazapine 30mg tablets raises concerns about supply chain integrity and patient access to this antidepressant. Monitoring the situation is crucial as it may lead to regulatory scrutiny and affect market dynamics.
Follow-up on any regulatory actions or further notifications regarding the affected batch and its distribution.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.